SCHEMBL18220201

SCHEMBL18220201

COCCNS(=O)(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N4CCCCC4)ccc3c2)n1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.42
GAA P10253 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KMT2A Q03164 5/20 0.33
MEN1 O00255 4/20 0.33
SLC16A3 O15427 2/20 0.33
SLC16A1 P53985 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220195 0.94 APP (0.43) APPALDH1A1MAPTKMT2AMEN1
SCHEMBL18220198 0.92 APP (0.43) APPGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL25610261 0.89 APP (0.34) APPSLC16A3SLC16A1CA1CA2
SCHEMBL18221449 0.85 APP (0.32) APP
SCHEMBL18220233 0.85 APP (0.32) APP
SCHEMBL18220004 0.84 APP (0.47) APPGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL18220214 0.83 KDM4E (0.31) GAAALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL18220136 0.83 APP (0.42) APPGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL18220197 0.83 APP (0.42) APPGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL25610291 0.83 APP (0.38) APPALDH1A1MAPTSMN1; SMN2SLC16A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2021-12-02 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885GAA 38/4885ALDH1A1 4151/4885
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885GAA 38/4885ALDH1A1 4151/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885GAA 38/4885ALDH1A1 4151/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885GAA 37/4885ALDH1A1 4226/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885GAA 37/4885ALDH1A1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.